Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration
6.3.2026 20:23:00 CET | Business Wire | Press Release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release.
1. 335 million locked-up shares — but two different categories
Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations.
A. 159 million shares (48% of locked-up shares) Depository receipt holders:
(i) ~97 million shares (30% of locked-up shares) — affiliate holders held through depositary receipts
Approximately 97 million shares (29% of all locked-up shares) are held by affiliates of the Company — a legal category that includes certain major institutional shareholders, executive officers, and members of the Board of Directors. Affiliate holders are subject to ongoing trading volume restrictions under Rule 144 of the US Securities Act that exist independently of, and are not removed by, the expiration of the IPO lock-up. Any affiliate wishing to sell shares is required to file the appropriate forms with the SEC concurrently with the placing of an order to execute a sale. As of the date of this release, no such filings have been made by any affiliate of the Company.
(ii) ~62 million shares (18% of lock-up shares) - non-affiliate shareholders held through depositary receipts
Approximately 62 million shares (18% of all locked-up shares) are held by non-affiliate shareholders of the Company through depositary receipts. These holders have elected to hold Depositary Receipts — a choice that allows them to retain their Class B share voting rights. Class B shares carry ten votes per share, compared to one vote per share for the Class A ordinary shares traded on the NYSE. Conversion to Depositary Receipts means these shares are not being transferred to broker-dealer accounts for open-market trading.
B. ~177 million shares — non-affiliate holders. The remaining approximately 177 million shares are held by non-affiliate pre-IPO shareholders whose lock-up expires March 9. Because Klarna Group plc is incorporated in England and Wales, pre-IPO ordinary shares are not held in DTC-eligible form. Before any such share can be sold through a US broker-dealer other than Computershare, the holder must complete a conversion process administered by Computershare, Klarna's transfer agent, involving the submission of a Letter of Transmittal. We are advised that Computershare's minimum processing time following receipt of a completed Letter of Transmittal is approximately 7 to 10 business days.
2. Status of the 177 million shares
3 million shares (1% of the 335 million) - Extended lock-up
Employees who received shares less than 6 months before the IPO hold what are known as "restricted securities" under the Securities Act of 1933. These shares carry a restrictive legend and cannot be freely transferred to a broker or sold publicly until certain conditions are met.
82 million shares (25% of the 335 million) — conversion process not initiated. These holders have not yet submitted a Letter of Transmittal to Computershare. Their shares cannot be transferred to a brokerage account until they do so and Computershare completes processing — a minimum of approximately 7 to 10 business days from submission. Holders who take no action with Computershare will continue to hold their shares in pre-IPO form and retain their existing share rights.
17 million shares (5%) — holders have elected to retain high-vote shares, not sell. These holders have submitted a Letter of Transmittal and elected to convert into Depositary Receipts — a choice that allows them to retain their Class B share voting rights. Class B shares carry ten votes per share, compared to one vote per share for the Class A ordinary shares traded on the NYSE. Conversion to Depositary Receipts means these shares are not being transferred to broker-dealer accounts for open-market trading.
25 million shares (7%) - transmittal received by Computershare. These holders have submitted a Letter of Transmittal yet to be processed by Computershare. These shares may become available for trading upon settlement. We cannot speak to the trading intentions of any of these holders.
50 million shares (15%) - transmittal received by Computershare and have opted to transfer to broker. These shares may become available for trading upon settlement. We cannot speak to the trading intentions of any of these holders.
3. The B-share voting right disincentive
Any pre-IPO shareholder who has not yet submitted a Letter of Transmittal holds Class B ordinary shares carrying ten votes per share. Initiating the conversion process to a broker-dealer account results in the permanent and irrevocable loss of Class B voting rights. This is a material structural consideration for any long-term shareholder independently of any trading intention.
4. Employees already had the opportunity to sell at IPO
Coverage suggesting that Monday represents the first opportunity for Klarna insiders and employees to sell is inaccurate. In connection with the September 2025 IPO, Klarna facilitated a liquidity programme under which employees holding vested RSUs were permitted to convert those awards into tradable ordinary shares and sell them shortly after trading commenced in the IPO, explicitly exempt from the standard six-month IPO lock-up. Employees were permitted to sell through September 30, 2025, with trading thereafter available during quarterly windows.
Additionally, during the IPO, existing shareholders sold 34.4m shares at $40.00 per ordinary share.
Shareholders who wished to realise liquidity have had multiple prior opportunities to do so. March 9, 2026 is not the first opportunity for pre-IPO shareholders to sell.
5. Summary
- Depository receipts (affiliate and non-affiliate): ~159M shares (48%)
- Letter of Transmittal not submitted: ~82M shares (24%)
- Elected Depositary Receipts: ~17M shares (5%)
- Opted to transfer to broker: ~50M shares (15%)
- To be processed by Computershare: ~25M shares (7%)
- Extended employee lock-up: ~3M shares (1%)
- Total: 335M shares (100%)
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding our future financial performance, share structure and applicable processes, business strategy, growth objectives, market opportunities, operational plans, including the outcome of legal cases. Words such as "believe," "expect," "anticipate," "intend," "plan," "will," "may," "could," "estimate," and similar expressions identify forward-looking statements.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied, including risks related to:
- Our ability to retain and grow consumer and merchant relationships;
- Competition and technological developments;
- Regulatory compliance and licensing requirements;
- Our ability to achieve expected benefits from our funding arrangements;
- Credit risk management and funding availability;
- General economic conditions and market volatility; and
- Our ability to expand into new markets and products.
Forward-looking statements reflect our views as of the date of this release and are based on information currently available to us. We undertake no obligation to update any forward-looking statements, except as required by law. Actual results may differ materially from those anticipated. Investors should not place undue reliance on these forward-looking statements and should review the risk factors in our filings with the SEC for a more complete discussion of risks.
About Klarna
Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna users and 3.4 million transactions per day, Klarna’s AI-powered payments and commerce network is empowering people to pay smarter with a mission to be available everywhere for everything. Consumers can pay with Klarna online, in-store and through Apple Pay & Google Pay. More than 966,000 retailers trust Klarna’s innovative solutions to drive growth and loyalty, including Uber, H&M, Saks, Sephora, Macy’s, Ikea, Expedia Group, Nike and Airbnb. Klarna is listed on the New York Stock Exchange (NYSE: KLAR). For more information, visit Klarna.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260306414202/en/
Contacts
press@klarna.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press Release
A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press Release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press Release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors30.4.2026 23:16:00 CEST | Press Release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom